BIVI logo

BIVI BioVie Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.80
-0.11 (-12.07%)

BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie …

Market Cap: $8.58Mbioviepharma.com

Price

No data yet.

Social Signal Score

42
5d
—
30d
44
4 mentions
—
60d
37
8 mentions
—
90d
44
16 mentions
—
news: 16

Analyst Ratings

5 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 0Sell 0Strong Sell 0

Revenue

$0.00
$0.00
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-12.12
$-12.12–$-12.12
1 analysts
FY2026
$-1.19
$-1.19–$-1.19
1 analysts
FY2027
$-0.63
$-0.63–$-0.63
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Cuong Viet Do
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
0.78
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-53.12
bioviepharma.com